SARM1 and neuropathy: However, our data remains consistent with the view that targeted knockdown or inhibition of SARM1 function is a promising strategy to ameliorate various neurological diseases, such as ALS or chemotherapy induced neuropathy, as this is unlikely to aberrantly affect PNS or CNS myelin in humans.